Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Guided Therapeutics (GTHP) over the last 15 years, with Q3 2025 value amounting to $2.1 million.

  • Guided Therapeutics' Non-cash Items fell 437.99% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 437.99%. This contributed to the annual value of $2.3 million for FY2024, which is 2510.04% up from last year.
  • Guided Therapeutics' Non-cash Items amounted to $2.1 million in Q3 2025, which was down 437.99% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' Non-cash Items ranged from a high of $2.4 million in Q1 2025 and a low of -$224000.0 during Q2 2021
  • In the last 5 years, Guided Therapeutics' Non-cash Items had a median value of $1.9 million in 2023 and averaged $1.7 million.
  • Data for Guided Therapeutics' Non-cash Items shows a peak YoY increase of 12780.85% (in 2021) and a maximum YoY decrease of 10353.31% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Guided Therapeutics' Non-cash Items stood at -$224000.0 in 2021, then surged by 688.43% to $1.3 million in 2022, then soared by 37.42% to $1.8 million in 2023, then increased by 25.1% to $2.3 million in 2024, then dropped by 8.32% to $2.1 million in 2025.
  • Its Non-cash Items stands at $2.1 million for Q3 2025, versus $2.2 million for Q2 2025 and $2.4 million for Q1 2025.